Vertex Pharmaceuticals Inc. Stock Rises 5.6%, Outperforms Peers
Dow Jones2026/08/10 20:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. rose 5.6% to $523.91 on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.1% to 7,753.11 and Dow Jones Industrial Average falling 0.1% to 53,975.98.
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals Inc. closed 1.8% below its 52-week high of $533.67, which the company achieved on July 7th.
The stock outperformed some of its peers, as AbbVie Inc. rose 0.8% to $247.97, Krystal Biotech Inc. rose 1.6% to $331.59, and Arcturus Therapeutics Holdings Inc. fell 4.86% to $7.05.
Trading volume totaled 2.7 million, compared to the 50-day average of 1.6 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 10, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
SK Hynix CEO: Memory chip shortage will persist until 2030
Crypto prices
More
